Chemotherapeutic Toxicity
80
17
17
27
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
1.3%
1 terminated out of 80 trials
96.4%
+9.9% vs benchmark
13%
10 trials in Phase 3/4
7%
2 of 27 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 27 completed trials
Clinical Trials (80)
Effect of a Novel Topical Composition on the Incidence of Severe Oral Mucositis in Head & Neck Cancer Radiated Patients and Quality of Life Assessed by PROMs.
App for Adverse Events to Oral Chemotherapy - Pilot Study
Early Diagnosis and Cardiovascular Risk Stratification in Children Exposed to Cancer Therapies
Daily Hand-Held Vibration Therapy
Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients
Evaluation of Cardiac and Endothelial Function in Children and Adolescents Treated With Anthracycline
The Effects of Clostridium Butyricum on Adverse Events During Adjuvant Chemotherapy for Colorectal Cancer
Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025
Serial PET MPI in Patients Undergoing Cancer Treatment
Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related Complications
The Effect of Home-Based Walking Program on Peripheral Neuropathy, Fatigue and Quality of Life
Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
At-Home Cardiac Rehabilitation for Adolescents at Risk for Heart Failure
Optimising Screening for the Cardiotoxic Effects of Cancer Therapy
Effectiveness of Mobile Based Monitoring System in the Management of Chemotherapy-Related Symptoms
Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.
Myocardial Perfusion and Fibrosis in Cancer Survivors